Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug Company

A comparison of prices for 89 generic drugs found that Medicare could have saved an estimated $3.3 billion (36%) in 2020 by purchasing at Mark Cuban Cost Plus Drug Company prices,with the largest potential savings on rosuvastatin ($241 million). These findings suggest that Medicare is substantially overpaying for many generic drugs and highlight inefficiencies in the existing pharmaceutical distribution and reimbursement system involving wholesalers, pharmacy benefit managers, and pharmacies.